IBDEI0PZ ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12765,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,12765,1,2,0)
 ;;=2^LYMPHOMA,PRIM CTR NERVOUS SYS
 ;;^UTILITY(U,$J,358.3,12765,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,12766,0)
 ;;=202.90^^75^791^33
 ;;^UTILITY(U,$J,358.3,12766,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12766,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,12766,1,2,0)
 ;;=2^LYMPHOMA,OTHER SITE
 ;;^UTILITY(U,$J,358.3,12766,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,12767,0)
 ;;=200.10^^75^791^35
 ;;^UTILITY(U,$J,358.3,12767,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12767,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,12767,1,2,0)
 ;;=2^LYMPHOSARCOMA
 ;;^UTILITY(U,$J,358.3,12767,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,12768,0)
 ;;=172.9^^75^791^36
 ;;^UTILITY(U,$J,358.3,12768,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12768,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,12768,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,12768,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,12769,0)
 ;;=199.0^^75^791^39
 ;;^UTILITY(U,$J,358.3,12769,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12769,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,12769,1,2,0)
 ;;=2^METASTATIC CA OF UNKN PRIMARY
 ;;^UTILITY(U,$J,358.3,12769,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,12770,0)
 ;;=203.00^^75^791^40
 ;;^UTILITY(U,$J,358.3,12770,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12770,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,12770,1,2,0)
 ;;=2^MULTIPLE MYELOMA
 ;;^UTILITY(U,$J,358.3,12770,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,12771,0)
 ;;=238.75^^75^791^41
 ;;^UTILITY(U,$J,358.3,12771,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12771,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,12771,1,2,0)
 ;;=2^MYELODYSPLASTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,12771,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,12772,0)
 ;;=157.9^^75^791^43
 ;;^UTILITY(U,$J,358.3,12772,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12772,1,1,0)
 ;;=1^157.9
 ;;^UTILITY(U,$J,358.3,12772,1,2,0)
 ;;=2^PANCREATIC CANCER
 ;;^UTILITY(U,$J,358.3,12772,2)
 ;;=^267103
 ;;^UTILITY(U,$J,358.3,12773,0)
 ;;=187.9^^75^791^44
 ;;^UTILITY(U,$J,358.3,12773,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12773,1,1,0)
 ;;=1^187.9
 ;;^UTILITY(U,$J,358.3,12773,1,2,0)
 ;;=2^PENILE CANCER
 ;;^UTILITY(U,$J,358.3,12773,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,12774,0)
 ;;=163.9^^75^791^46
 ;;^UTILITY(U,$J,358.3,12774,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12774,1,1,0)
 ;;=1^163.9
 ;;^UTILITY(U,$J,358.3,12774,1,2,0)
 ;;=2^PLEURAL CANCER
 ;;^UTILITY(U,$J,358.3,12774,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,12775,0)
 ;;=185.^^75^791^47
 ;;^UTILITY(U,$J,358.3,12775,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12775,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,12775,1,2,0)
 ;;=2^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,12775,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,12776,0)
 ;;=287.9^^75^791^48
 ;;^UTILITY(U,$J,358.3,12776,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12776,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,12776,1,2,0)
 ;;=2^PURPURA/OTH HEMORRHAGIC COND
 ;;^UTILITY(U,$J,358.3,12776,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,12777,0)
 ;;=154.3^^75^791^49
 ;;^UTILITY(U,$J,358.3,12777,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12777,1,1,0)
 ;;=1^154.3
 ;;^UTILITY(U,$J,358.3,12777,1,2,0)
 ;;=2^RECTAL CANCER
 ;;^UTILITY(U,$J,358.3,12777,2)
 ;;=^267092
 ;;^UTILITY(U,$J,358.3,12778,0)
 ;;=189.9^^75^791^64
 ;;^UTILITY(U,$J,358.3,12778,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,12778,1,1,0)
 ;;=1^189.9
 ;;^UTILITY(U,$J,358.3,12778,1,2,0)
 ;;=2^URINARY ORGAN CANCER
 ;;^UTILITY(U,$J,358.3,12778,2)
 ;;=^267269
 ;;^UTILITY(U,$J,358.3,12779,0)
 ;;=142.9^^75^791^51
